Company / Cash & Equivalents
Perspective Therapeutics, Inc. Cash & Equivalents History
FY2013-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$55.9M
FY2022
5-year range
$2.4M / $55.9M
FY2018-FY2022
Trend
+2236.5%
vs FY2021
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents changed +2237% YoY in FY2022, a notable deviation from the 9-year average annual change of +265%.
Based on SEC 10-K filings.
$56M in FY2022 with a 5-year CAGR of +60.6%.
Improved from $5M to $56M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +178.0%
- 5-Year CAGR
- +60.6%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +60.6%, indicating consistent growth.
- In FY2022, cash & equivalents increased 2236.5% year-over-year.
- Lowest cash & equivalents in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 5.43 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2022 | $55.9M | +2236.5% |
| FY2021 | $2.4M | -55.1% |
| FY2020 | $5.3M | +104.8% |
| FY2019 | $2.6M | -56.2% |
| FY2018 | $5.9M | +13.5% |
| FY2017 | $5.2M | -31.9% |
| FY2016 | $7.7M | +164.8% |
| FY2015 | $2.9M | +8.5% |
| FY2014 | $2.7M | +0.0% |
| FY2013 | $2.7M | - |
As of FY2022 · SEC 10-K · Updated Jun 24, 2026